Mo Mengwu, Wang Feiyu, Zhang Huiming, Zhang Ying, Yang Chaoyong, Shang Jinbiao, Zhu Zhi
MOE Key Laboratory of Spectrochemical Analysis and Instrumentation, State Key Laboratory of Physical Chemistry of Solid Surfaces, Key Laboratory for Chemical Biology of Fujian Province, Department of Chemical Biology, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, China.
Innovation Laboratory for Sciences and Technologies of Energy Materials of Fujian Province, Xiamen, China.
Angew Chem Int Ed Engl. 2025 Jun 2;64(23):e202501857. doi: 10.1002/anie.202501857. Epub 2025 Apr 8.
Targeted protein degradation (TPD) represents a potent therapeutic strategy aimed at dismantling disease-associated target proteins. PROTAC is the most widely developed technique for intracellular protein degradation, while its degradation ability on membrane proteins has been hindered by the need for complex synthetic processes and limited permeability. In this study, we developed the membrane-bounded intracellular E3 ubiquitin ligase-targeting chimeras (MembTACs) that simultaneously recruit intracellular E3 ubiquitin ligase and bind to the desired membrane proteins for targeted degradation of membrane proteins. We demonstrate that the MembTACs can effectively utilize intracellular E3 ubiquitin ligase to degrade the therapeutically relevant membrane proteins of EpCAM and Met via the proteasome pathway. We anticipate that the new platform will expand the range of PROTAC applications and provide a new dimension for targeted membrane protein degradation.
靶向蛋白质降解(TPD)是一种旨在拆解与疾病相关的靶蛋白的有效治疗策略。PROTAC是细胞内蛋白质降解领域发展最为广泛的技术,然而其对膜蛋白的降解能力因合成过程复杂且渗透性有限而受到阻碍。在本研究中,我们开发了膜结合细胞内E3泛素连接酶靶向嵌合体(MembTACs),它能够同时招募细胞内E3泛素连接酶并与所需的膜蛋白结合,从而实现对膜蛋白的靶向降解。我们证明,MembTACs能够通过蛋白酶体途径有效利用细胞内E3泛素连接酶降解治疗相关的膜蛋白EpCAM和Met。我们预计,这个新平台将扩大PROTAC的应用范围,并为靶向膜蛋白降解提供新的维度。